Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination

Gastric Cancer

Volumn 19, Issue 4, 2016, Pages 1052-1065

  Yamaguchi, Takahisa ^a   Fushida, Sachio ^a   Yamamoto, Yasuhiko ^a   Tsukada, Tomoya ^a   Kinoshita, Jun ^a   Oyama, Katsunobu ^a   Miyashita, Tomoharu ^a   Tajima, Hidehiro ^a   Ninomiya, Itasu ^a   Munesue, Seiichi ^a   Harashima, Ai ^a   Harada, Shinichi ^a   Yamamoto, Hiroshi ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Amphiregulin; Gastric cancer; Macrophage; Peritoneal dissemination; Tumor associated macrophage

Indexed keywords

AMPHIREGULIN; ANTIGEN; B7 ANTIGEN; CD163 ANTIGEN; CD204 ANTIGEN; CD68 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERSTITIAL COLLAGENASE; MESSENGER RNA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; IL10 PROTEIN, HUMAN; IL12B PROTEIN, HUMAN; TUMOR MARKER; VEGFA PROTEIN, HUMAN; VEGFC PROTEIN, HUMAN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER STAGING; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; DISEASE COURSE; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; MACROPHAGE; METABOLISM; PATHOLOGY; PERITONEUM TUMOR; PHOSPHORYLATION; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SECONDARY; STOMACH TUMOR; TUMOR INVASION;

AGED; ANIMALS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-10; INTERLEUKIN-12 SUBUNIT P40; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PHENOTYPE; PHOSPHORYLATION; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84948969110     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-015-0579-8     Document Type: Article

References (42)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–43.
2. Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, Ninomiya I, et al. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep. 2008;19:1305–10.
3. Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, et al. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71:1265–72.
4. Shimada S, Tanaka E, Marutsuka T, Honmyo U, Tokunaga H, Yagi Y, et al. Extensive intraoperative peritoneal lavage and chemotherapy for gastric cancer patients with peritoneal free cancer cells. Gastric Cancer. 2002;5:168–72.
5. Yonemura Y, Kawamura T, Nojima N, Bandou E, Keizou T, Fujita H, et al. Postoperative results of left upper abdominal evisceration for advanced gastric cancer. Hepatogastroenterology. 2010;47:571–4.
6. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.
7. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, et al. Randomized phase III study of 5-fluorouracil continuous infusion vs sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013;43:972–80.
8. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.
9. Tlsty TD. Stromal cells can contribute oncogenic signals. Semin Cancer Biol. 2001;11:97–104.
10. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67:10123–8.
11. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316:1324–31.
12. Tsukada T, Fushida S, Harada S, Yagi Y, Kinoshita J, Oyama K, et al. The role of human peritoneal mesothelial cells in the fibrosis and progression of gastric cancer. Int J Oncol. 2012;41:476–82.
13. Terai S, Fushida S, Tsukada T, Kinoshita J, Oyama K, Okamoto K, et al. Bone marrow derived “fibrocytes” contribute to tumor proliferation and fibrosis in gastric cancer. Gastric Cancer. 2015;18:306–13.
14. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
15. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605–12.
16. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216:15–24.
17. Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for angioimmunoblastic T-cell lymphoma (AITL). Pathol Int. 2010;60:278–83.
18. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010;101:1913–9.
19. Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 2011;102:1424–31.
20. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Okumura H, Matsumoto M, et al. Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res. 2003;23:4079–83.
21. Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134:32–42.
22. Jaguin M, Houlbert N, Fardel O, Lecureul V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol. 2013;281:51–61.
23. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.
24. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.
25. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarized population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.
26. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65.
27. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007;31:1458–68.
28. Galizia G, Lieto E, Ferraraccio F, Vita De, Castellano P, Orditura M, et al. Prognositic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol. 2006;13:823–35.
29. Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, et al. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res. 2011;1:3619–30.
30. Liu XY, Miao ZF, Zhao TT, Wang ZN, Xu YY, Gao J, et al. Milky spot macrophages remodeled by gastric cancer cells promote peritoneal mesothelial cell injury. Biochem Biophys Res Commun. 2013;439:378–83.
31. Wyler L, Napoli CU, Ingold B, Sulser T, Heikenwälder M, Schrami P, et al. Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. Br J Cancer. 2014;110:686–94.
32. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007;67:9417–24.
33. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22:231–7.
34. Fushida S, Oyama K, Kinoshita J, Yagi Y, Okamoto K, Tajima H, et al. VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody. Onco Targets Ther. 2013;6:1445–51.
35. Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol Lett. 2009;123:97–102.
36. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–68.
37. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787–95.
38. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15:69–79.
39. Anzai H, Kitadai Y, Bucana CD, Sanchez R, Omoto R, Fidler IJ. Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur J Cancer. 1998;34:558–65.
40. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH, et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008;52:738–46.
41. Weng X, Zhang H, Ye J, Kan M, Liu F, Wang T, et al. Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer. Sci Rep. 2015;11:10154.
42. Brown CL, Meise KS, Plowman GD, Coffey RJ, Dempsey PJ. Cell surface ectodomain cleavage of human amphiregulin precursor is sensitive to a metalloprotease inhibitor. Release of a predominant N-glycosylated 43-kDa soluble form. J Biol Chem. 1998;273:17258–68.